Amylyx Pharmaceuticals Inc. discovers and develops novel treatments for communities with high unmet medical needs. The company's clinical pipeline is led by avexitide, a first-in-class GLP-1 receptor antagonist being evaluated for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism. Additional investigational programs include AMX0035 for Wolfram syndrome, AMX0114 (an antisense oligonucleotide) for amyotrophic lateral sclerosis (ALS), and AMX0318 for PBH and other rare diseases. Previously, the company commercialized the ALS treatment Relyvrio, which was voluntarily withdrawn from the market in 2024 following a Phase 3 trial that did not meet its primary endpoints. Amylyx operates globally with offices in the United States, Canada, and the Netherlands.
